COLUMN GROUP L P
CIK 1347769 · last filed 2023-11-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$37.87M
Companies
3
Total Filings
21
Lifetime Open-Market Net
$67.18M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | 12,053,195 | $1.54 | $18.56M | $67.18M | 19 | 2023-11-17 |
| NRIX | 10%+ Owner | 1,533,716 | $24.69 | $37.87M | $0 | 1 | 2021-05-07 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 2,607,060 | $33.99 | $88.61M | $0 | 1 | 2020-12-16 |
Recent Filings · Page 2 of 3
21 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-11 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +1,144,400 | $12.53M | EDGAR |
| 2022-01-26 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +8,497,010 | $0 | EDGAR |
| 2021-05-07 | NRIX | Other (J) | −5,356,402 | $0 | EDGAR |
| 2020-12-16 | CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Exer (X) | +90,321 | $140.0K | EDGAR |
| 2020-08-17 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +385,878 | $6.81M | EDGAR |
| 2020-03-25 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +1,204,720 | $14.32M | EDGAR |
| 2019-11-13 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +60 | $720 | EDGAR |
| 2019-11-06 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +84,090 | $1.01M | EDGAR |
| 2019-11-06 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +33,636 | $403.3K | EDGAR |
| 2019-10-21 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +849,390 | $9.83M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.